Plant Name: Agathis lanceolata
Taxonomic Information:
Plant ID: NPO1787
Plant Latin Name: Agathis lanceolata
Taxonomy Genus: Agathis
Taxonomy Family: Araucariaceae
Plant External Links:
NCBI TaxonomyDB:
56989
Plant-of-the-World-Online:
676644-1
Used in Medicines:
Unknown.
Geographical Distribution:
New Caledonia
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| PTPN1; | |
| TDP1; HKDC1; AKR1B1; HSD17B10; USP2; | |
| CA2; CA1; CA12; CA9; CA7; CA5A; CA3; CA14; CA5B; CA6; | |
| MMP9; MMP1; MMP2; | |
| NFKB1; | |
| LMNA; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP3A4; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HKDC1 | Putative hexokinase HKDC1 | Q2TB90 | CHEMBL1741200 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 9.168E-13 | 2.852E-09 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, PTPN1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.723E-27 | 3.752E-23 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.066E-06 | 5.533E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.399E-21 | 1.523E-17 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.341E-20 | 3.996E-16 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 2.028E-05 | 2.325E-02 | CA1, CA2 |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 3.524E-05 | 3.837E-02 | AKR1B1, CA2, CA9, LMNA, MAPT, MMP9, NFKB1, PTPN1, TDP1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.870E-27 | 7.240E-25 | CA12, CA1, CA3, CA5B, CA2, CA5A, CA7, CA6, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.376E-05 | 6.331E-04 | MMP1, MMP2, MMP9 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.004E-03 | 1.847E-02 | MMP1, MMP2, MMP9, NFKB1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 5.396E-04 | 1.413E-02 | HKDC1, AKR1B1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 6.144E-04 | 1.413E-02 | HKDC1, AKR1B1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 5.962E-03 | 5.392E-02 | MMP2, NFKB1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.996E-03 | 4.593E-02 | CA2, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 5.735E-03 | 5.392E-02 | MMP2, MMP9 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 6.193E-03 | 5.392E-02 | HKDC1, NFKB1 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00524 | Butirosin and neomycin biosynthesis | 5.737E-03 | 5.392E-02 | HKDC1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; MMP2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; MMP9; MMP2; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
